Copyright
©The Author(s) 2020.
World J Psychiatr. Jul 19, 2020; 10(7): 162-174
Published online Jul 19, 2020. doi: 10.5498/wjp.v10.i7.162
Published online Jul 19, 2020. doi: 10.5498/wjp.v10.i7.162
Table 2 Summary of publications
| Ref. | Year | Number of participants | Age (yr) | Setting | Comparators | Duration |
| Ballard et al[44] | 2018 | 181 (pimavanserin n = 90; placebo n = 91) | ≥ 50 | Nursing homes | 17 mg × 2 tablets pimavanserin vs placebo (2 tablets) | 12 wk |
| Ballard et al[45] | 2019 | 181 (pimavanserin n = 90; placebo n = 91) | ≥ 50 | Nursing homes | 34 mg pimavanserin vs placebo | 12 wk |
- Citation: Srinivasan S, Tampi RR, Balaram K, Kapoor A. Pimavanserin for the treatment of psychosis in Alzheimer’s disease: A literature review. World J Psychiatr 2020; 10(7): 162-174
- URL: https://www.wjgnet.com/2220-3206/full/v10/i7/162.htm
- DOI: https://dx.doi.org/10.5498/wjp.v10.i7.162